Stock BBIO BRIDGEBIO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Real-time Estimate Cboe BZX
Other stock markets
 01:30:41 2024-05-21 pm EDT 		5-day change 1st Jan Change
29.02 USD -1.69% Intraday chart for BridgeBio Pharma, Inc. -0.36% -28.55%
May. 16 Transcript : BridgeBio Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
May. 06 Certain Restricted Stock Unit Awards of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BridgeBio Pharma : BBIO BBP 418 – MENA 2024 – Oral Presentation
PU
BridgeBio Pharma : Bank of America Merrill Lynch Healthcare Conference 2024 Presentation
PU
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
GL
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
GL
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – NT-proBNP Insights from the ATTRibute-CM Study
PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD in ATTRibute-CM
PU
Bridgebio launches bridgebio oncology therapeutics with $200m of private external capital to accelerate the development of its novel precision oncology pipeline
AQ
BridgeBio Pharma: Q1 Earnings Snapshot
AQ
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
GL
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
AQ
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
GL
BridgeBio Pharma : BBIO – BBO-8520 – 2024 AACR – Rapid and Complete Blockade of Effector Binding Results
PU
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
BridgeBio Pharma Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 study in Patients with Transthyretin Amyloid Cardiomyopathy
AQ
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
AQ
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
GL
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ACMG 2024 Genetic Testing
PU
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BBIO Stock
  4. News BridgeBio Pharma, Inc.
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW